Literature DB >> 33446693

Trends in the kidney cancer mortality-to-incidence ratios according to health care expenditures of 56 countries.

Wen-Wei Sung1,2,3, Po-Yun Ko2, Wen-Jung Chen1,2,3, Shao-Chuan Wang4,5,6, Sung-Lang Chen7,8,9.   

Abstract

The incidence and mortality rates in kidney cancer (KC) are increasing. However, the trends for mortality have varied among regions over the past decade, which may be due to the disparities in medical settings, such as the availability of frequent imaging examinations and effective systemic therapies. The availability of these two medical options has been proven to be positively correlated with a favorable prognosis in KC and may be more common in countries with better health care systems and greater expenditures. The delicate association between the trends in clinical outcomes in KC and health care disparities warrant detailed observation. We applied a delta-mortality-to-incidence ratio (δMIR) for KC to compare two years as an index for the improvement in clinical outcomes and the mortality-to-incidence ratio (MIR) of a single year to evaluate their association with the Human Development Index (HDI), current health expenditure (CHE) per capita, and CHE as a percentage of gross domestic product (CHE/GDP) by using linear regression analyses. A total of 56 countries were included based on data quality reports and missing data. We discovered that the HDI, CHE per capita, and CHE/GDP were negatively correlated with the MIRs for KC (p < 0.001, p < 0.001, and p < 0.001, respectively). No significant association was observed between the δMIRs and the HDI, CHE per capita, and CHE/GDP among the included countries, and only the CHE/GDP shows a trend toward significance. Interestingly, the δMIRs related with an increase in relative health care investment include δCHE per capita and δCHE/GDP.

Entities:  

Year:  2021        PMID: 33446693     DOI: 10.1038/s41598-020-79367-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  30 in total

1.  The cost-effectiveness of immediate treatment, percutaneous biopsy and active surveillance for the diagnosis of the small solid renal mass: evidence from a Markov model.

Authors:  Marta E Heilbrun; Junhua Yu; Kenneth J Smith; Christopher B Dechet; Ronald J Zagoria; Mark S Roberts
Journal:  J Urol       Date:  2011-11-16       Impact factor: 7.450

2.  The application of the mortality-to-incidence ratio for the evaluation of cancer care disparities globally.

Authors:  Vasu Sunkara; James R Hébert
Journal:  Cancer       Date:  2015-10-20       Impact factor: 6.860

3.  Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.

Authors:  Luca Cindolo; Jean-Jacques Patard; Paolo Chiodini; Luigi Schips; Vincenzo Ficarra; Jacques Tostain; Alexandre de La Taille; Vincenzo Altieri; Bernard Lobel; Richard E Zigeuner; Walter Artibani; François Guillé; Claude C Abbou; Luigi Salzano; Ciro Gallo
Journal:  Cancer       Date:  2005-10-01       Impact factor: 6.860

Review 4.  Renal cell carcinoma.

Authors:  W Kimryn Rathmell; Paul A Godley; Brian I Rini
Journal:  Curr Opin Oncol       Date:  2005-05       Impact factor: 3.645

5.  Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.

Authors:  Eduard Vrdoljak; Gyorgy Bodoky; Jacek Jassem; Razvan Popescu; Robert Pirker; Tanja Čufer; Semir Bešlija; Alexandru Eniu; Vladimir Todorović; Katerina Kopečková; Galia Kurteva; Zorica Tomašević; Agim Sallaku; Snezhana Smichkoska; Žarko Bajić; Branimir Sikic
Journal:  Oncologist       Date:  2018-09-04

6.  A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma.

Authors:  Maximiliano Sorbellini; Michael W Kattan; Mark E Snyder; Victor Reuter; Robert Motzer; Manlio Goetzl; James McKiernan; Paul Russo
Journal:  J Urol       Date:  2005-01       Impact factor: 7.450

7.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.

Authors:  Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

Review 10.  Imaging for the diagnosis and response assessment of renal tumours.

Authors:  Sabrina H Rossi; Davide Prezzi; Christian Kelly-Morland; Vicky Goh
Journal:  World J Urol       Date:  2018-06-13       Impact factor: 4.226

View more
  5 in total

1.  Challenges in Diversity, Equity, and Inclusion in Research and Clinical Oncology.

Authors:  Wafik S El-Deiry; Giuseppe Giaccone
Journal:  Front Oncol       Date:  2021-03-24       Impact factor: 6.244

2.  Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries.

Authors:  Rachel Giles; Deborah Maskens; Robert Bick; Robin Martinez; Malcolm Packer; Daniel Heng; James Larkin; Axel Bex; Michael Jewett; Eric Jonasch; Sara MacLennan
Journal:  Eur Urol Open Sci       Date:  2022-01-17

Review 3.  New imaging technologies for robotic kidney cancer surgery.

Authors:  Stefano Puliatti; Ahmed Eissa; Enrico Checcucci; Pietro Piazza; Marco Amato; Stefania Ferretti; Simone Scarcella; Juan Gomez Rivas; Mark Taratkin; Josè Marenco; Ines Belenchon Rivero; Karl-Friedrich Kowalewski; Giovanni Cacciamani; Ahmed El-Sherbiny; Ahmed Zoeir; Abdelhamid M El-Bahnasy; Ruben De Groote; Alexandre Mottrie; Salvatore Micali
Journal:  Asian J Urol       Date:  2022-06-01

4.  Thais savignyi tissue extract: bioactivity, chemical composition, and molecular docking.

Authors:  Mohamed R Habib; Ahmed A Hamed; Rasha E M Ali; Khaled M Zayed; Rasha M Gad El-Karim; Rehab Sabour; Hanaa M Abu El-Einin; Mosad A Ghareeb
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

5.  Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro.

Authors:  Igor Tsaur; Anita Thomas; Emine Taskiran; Jochen Rutz; Felix K-H Chun; Axel Haferkamp; Eva Juengel; Roman A Blaheta
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.